[Featured Stock] Miko, Subsidiary Sinjong Corona Pursues 'Special Listing' for Airport, Port, Terminal COVID-19 Rapid Diagnosis Technology Within 1 Hour

[Asia Economy Reporter Yoo Hyun-seok] Miko's stock price is on the rise. It appears that the news of its subsidiary, MikobioMed, passing the technical evaluation for KOSDAQ special technology listing has had an impact.

As of 10:57 AM on the 30th, Miko was trading at 5,840 KRW, up 6.96% (380 KRW) compared to the previous trading day.

Founded in 2009, MikobioMed received an A grade from both NICE D&B and eCredible, evaluation agencies designated by the Korea Exchange. The company has developed and commercialized Lab-on-a-Chip (Lab-on-a-Chip·Lab Chip) based molecular diagnostic equipment and kits that rapidly and accurately extract, amplify, and diagnose genes from pathogens such as bacteria and viruses.

MikobioMed possesses in vitro diagnostic technology that quickly and accurately delivers on-site diagnostic results to doctors or the Korea Disease Control and Prevention Agency via smartphones at a low cost. It has secured patents in 17 advanced countries and commercialized diagnostics for food poisoning and high-risk diseases.

It is expected to contribute to disease management and control through wireless communication by rapidly and accurately measuring new viruses like the recently problematic novel coronavirus or highly fatal high-risk viruses on-site for confirmation. The company explained that it can provide a confirmed diagnosis within an hour at airports, ports, terminals, hospitals, and other locations.

In cases of fever, it simultaneously performs multiplex diagnosis of 14 types of disease-causing pathogens including influenza, Zika, dengue, malaria, and yellow fever. It can also perform on-site diagnosis of animal-related viruses such as African swine fever and food-related viruses causing food poisoning.

MikobioMed aims to be listed on the KOSDAQ market within this year.

This content was produced with the assistance of AI translation services.